These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 16097922)

  • 1. Tumour necrosis factor inhibitors.
    Nash PT; Florin TH
    Med J Aust; 2005 Aug; 183(4):205-8. PubMed ID: 16097922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
    Breedveld FC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-TNF alpha in the treatment of psoriatic arthritis].
    Claudepierre P; Wendling D; Cohen JD
    Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
    Wiedmann MW; Mössner J; Baerwald C; Pierer M
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP; Liossis SN; Sfikakis PP
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O; Roux CH; Albert C; Breuil V; Aknouche N; Ruitord S; Mousnier A; Euller-Ziegler L
    Joint Bone Spine; 2007 Mar; 74(2):148-54. PubMed ID: 17368068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT; Adorni G
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K; Hartley L; Solanki K; White D
    N Z Med J; 2015 May; 128(1415):34-40. PubMed ID: 26117510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic therapy of psoriatic arthritis.
    Gladman DD
    Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G; Strehblow C; Fasching P
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.